A wound healing and tissue repair composition with low molecular weight collagen and bioactive glass is provided. The wound healing and tissue repair composition with low molecular weight collagen is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The main ingredients of the formulated composition are collagen having a molecular weight of about 1,000 Da or less and sourced from multiple sources, such as bovine sourced collagen and marine sourced collagen. The composition may further comprise hydrolyzed whey. The collagen may be hydrolyzed collagen, native collagen, or a mixture thereof. The composition may include one or more additives, including bioactive glass, polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, a glucosamine salt, and a mixture thereof.

The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.

The composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, and may include high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof. The collagen may be derived from two or more different sources, and may be combined with hydrolyzed whey and/or elastin.

The composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, and may include high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof. The collagen may be derived from two or more different sources, and may be combined with hydrolyzed whey and/or elastin.

The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy.

The present invention relates to a use of collagen hydrolysate after intensive care unit (ICU) stay. The collagen hydrolysate improves the recovery and prevents and/or treats post intensive care syndrome (PICS) after ICU stay. The collagen hydrolysate is preferably administered as a supplement in the context of ICU stay and/or PICS. Collagen hydrolysate is generally-accepted to be safe and therefore can be taken as a preventive and long-term measure.

Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAX effectively improved the sensory function in patients with diabetic neuropathy.

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

The composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, and may include high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof. The collagen may be derived from two or more different sources, and may be combined with hydrolyzed whey and/or elastin.

The composition for tissue/cell repair facilitates healing of damaged tissues, promoting tissue and cell growth, protecting cells and tissues, and reducing scar tissue. The composition includes hydrolyzed collagen, and may include high molecular weight hydrolyzed collagen. The hydrolyzed collagen may be combined with native collagen and/or at least one other therapeutic agent. For example, the therapeutic agent may be a polysulfated glycosaminoglycan, a glucosamine salt, or mixtures thereof. The collagen may be derived from two or more different sources, and may be combined with hydrolyzed whey and/or elastin.